NABRIVA THERAPEUTICS
Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA® (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP). Nabriva Therapeutics is also developing CONTEPO™ (fosfomycin) for injection, a potential first-in-class epox... ide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis. Nabriva entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO® (tedizolid phosphate) in the United States and certain of its territories.
NABRIVA THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Medical
Founded:
2001-01-01
Address:
Vienna, Wien, Austria
Country:
Austria
Website Url:
http://www.nabriva.com
Total Employee:
101+
Status:
Active
Contact:
(430) 174-0930
Email Addresses:
[email protected]
Total Funding:
325.87 M USD
Technology used in webpage:
LetsEncrypt IPv6 New Relic Mobile Optimized FLoC Opt-Out FLoC Drupal Akamai Hosted Adobe Dynamic Tag Management LiveChat
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2018-07-25 | Zavante Therapeutics | Zavante Therapeutics acquired by Nabriva Therapeutics | N/A |
Investors List
Armentum Partners
Armentum Partners investment in Post-IPO Debt - Nabriva Therapeutics
Hercules Capital
Hercules Capital investment in Post-IPO Debt - Nabriva Therapeutics
Novartis Venture Fund
Novartis Venture Fund investment in Series B - Nabriva Therapeutics
GLS Ventures
GLS Ventures investment in Series B - Nabriva Therapeutics
EcoR1 Capital
EcoR1 Capital investment in Series B - Nabriva Therapeutics
Wellcome Trust
Wellcome Trust investment in Series B - Nabriva Therapeutics
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series B - Nabriva Therapeutics
OrbiMed
OrbiMed investment in Series B - Nabriva Therapeutics
Phase4 Partners
Phase4 Partners investment in Series B - Nabriva Therapeutics
Vivo Capital
Vivo Capital investment in Series B - Nabriva Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2021-10-01 | Nabriva Therapeutics Appoints Dr. Christine Guico-Pabia, M.D., as Chief Medical Officer |
Official Site Inspections
http://www.nabriva.com Semrush global rank: 8.11 M Semrush visits lastest month: 365
- Host name: 52.176.165.69
- IP address: 52.176.165.69
- Location: Des Moines United States
- Latitude: 41.6006
- Longitude: -93.6112
- Metro Code: 679
- Timezone: America/Chicago
- Postal: 50307
More informations about "Nabriva Therapeutics"
Commercial Stage Biopharmaceutical Company | Nabriva.com
Nabriva is a commercial-stage biopharmaceutical company engaged in the research & development of novel antibiotics to treat serious infections, with a current focus on the …See details»
New Antibiotics | Nabriva Therapeutics | Nabriva.com
Nabriva Therapeutics is committed to developing new antibiotics to treat infectious diseases. Our dedicated team includes people with extensive science and industry experience and a shared passion for addressing the increasingly …See details»
Novel Antibiotics | Lefamulin | Nabriva.com
Find information about Nabriva's novel antibiotic research and product pipeline. Nabriva is committed to the development of Novel Antibiotics, with pipeline work focusing on Lefamulin …See details»
Nabriva Therapeutics - Crunchbase Company Profile
Nabriva Therapeutics is a biopharmaceutical company focused on the R&D of antibiotics for use in community and hospital infections. View contacts for …See details»
Nabriva Therapeutics - Craft
Oct 21, 2024 · Our goal is to become a fully integrated biopharmaceutical company focused on the research, development and commercialization of novel anti-infective products. Nabriva …See details»
Org Chart Nabriva Therapeutics - The Official Board
Nabriva Therapeutics is followed by less than 10 members.See details»
Nabriva Announces Changes to its Board of Directors
Jun 2, 2021 · Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.See details»
Company Nabriva Therapeutics plc - MarketScreener.com
Dec 31, 2014 · The Company is engaged in the commercialization and development of anti-infective agents to treat serious infections. The Company's product is XENLETA (lefamulin …See details»
Nabriva Therapeutics Provides Corporate Update - Yahoo Finance
DUBLIN, Ireland, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV) today announced that, after an assessment of strategic options, its Board of Directors …See details»
Nabriva Therapeutics - Overview, News & Similar companies
Nov 7, 2022 · Who is Nabriva Therapeutics. Founded in 2006, Nabriva Therapeutics is a biopharmaceutical company that engages in the development and commercialization of novel …See details»
Careers | Nabriva.com
At Nabriva, we have some of the industry's best and brightest people dedicated to making novel antibiotics accessible to patients in need. Developing new treatments for serious diseases …See details»
Biotech firm Nabriva to wind down | C&EN Global Enterprise
Jan 16, 2023 · Nabriva Therapeutics says it is going to wind down, becoming the latest antibiotic developer to fail commercially. Nabriva was formed in 2006 from Sandoz’s antibiotic research …See details»
Antibiotic developer Nabriva to wind down - Chemical
Jan 12, 2023 · Nabriva Therapeutics says it is going to wind down, becoming the latest antibiotic developer to fail commercially. Nabriva was formed in 2006 from Sandoz’s antibiotic research …See details»
Nabriva Therapeutics plc (NBRVF) - Yahoo Finance
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections.See details»
Nabriva Therapeutics Reports Fourth Quarter and Full Year 2021 ...
DUBLIN, Ireland, March 29, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of …See details»
Nabriva Corporate > About Nabriva > Our Products
© Nabriva Therapeutics plc, Ireland Registration No. 599588, 25-28 North Wall Quay, Dublin 1, IrelandSee details»
Nabriva Therapeutics Pivoting Strategic Focus Reports Third …
DUBLIN, Ireland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of …See details»
News & Publications | Nabriva.com
Find Nabriva news & publication information. Stay up to date on what’s happening at Nabriva Therapeutics includes downloadable poster presentations and published articles on the latest …See details»
The Fate of Another Antibiotic Biotech - Nabriva
Jan 16, 2023 · Last week, a small, publicly held antibiotic biotech, Nabriva, announced that it would wind down its operations. Everyone still there lost their jobs.See details»
Nabriva Therapeutics Provides Business Update and Announces …
Jan 10, 2022 · DUBLIN, Ireland and FORT WASHINGTON, Pa., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company …See details»